文献速递肾癌与肾肿瘤

99mTc-甲氧基异丁基异腈SPECT/CT对肾脏肿物定性的效能:前瞻性扫描-切除试验与临床经验的联合结果

Performance of 99mTc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience.
PubMed 文献 · J Urol · 2025-12-23

该研究联合前瞻性扫描-切除试验与常规临床队列,评估99mTc-sestamibi SPECT/CT对肾脏肿物组织学定性的准确性。结果显示该分子影像有助于对不确定肾脏肿物进行风险分层,但存在假阳性和假阴性,需在共享决策中权衡。

要点

  • 99mTc-sestamibi SPECT/CT可无创地对不确定肾脏肿物进行风险分层。
  • 透明细胞RCC多表现为冷肿瘤,嗜酸细胞瘤多表现为热肿瘤。
  • 存在假阳性和假阴性,需结合共享决策指导后续评估与管理。

核心结论

  • 99mTc-sestamibi SPECT/CT是有效风险分层不确定肾脏肿物的新方法,但需警惕假阳性和假阴性并在共享决策中权衡。

研究设计与样本

  • 联合分析两个队列:一个来自前瞻性扫描-切除临床试验,另一个来自常规临床诊疗。
  • 按组织学分层分析99mTc-sestamibi SPECT/CT的肾脏肿物阳性率(即「热肿瘤」),并以灵敏度和特异度衡量诊断效能。

主要发现

  • 大多数透明细胞RCC(97%)以及乳头状或透明细胞乳头状RCC(80%-84%)为冷肿瘤。
  • 嫌色细胞RCC表现为热或冷的可能性相当(52% vs 48%)。
  • 手术切除的嗜酸细胞瘤倾向于表现为热肿瘤(69%),临床队列中活检为嗜酸性肿瘤的阳性率更高(87%)。

关键数值与推荐

  • 肾脏肿物阳性率按组织学分层:透明细胞RCC 97%为冷,乳头状或透明细胞乳头状RCC 80%-84%为冷,嫌色细胞RCC热52% vs 冷48%,手术切除嗜酸细胞瘤热69%,临床队列活检嗜酸性肿瘤热87%。
  • 诊断效能以灵敏度和特异度衡量,用于识别感兴趣的组织学分组。

临床怎么用

  • 可用于对不确定肾脏肿物进行无创风险分层,辅助鉴别良性/惰性肿瘤与侵袭性RCC。
  • 解读结果时需考虑假阳性和假阴性,并与患者共享决策以指导进一步评估和管理。

局限性

  • 队列存在异质性。
  • 临床队列中使用活检作为组织学诊断依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Anatomic imaging and biopsy have limitations in the risk stratification of indeterminate renal masses. Molecular imaging offers opportunities to improve noninvasive risk stratification. 99mTc-sestamibi is a mitochondrial imaging agent that has shown increased uptake in benign/indolent renal tumors and a lack of uptake in aggressive renal cell carcinomas (RCCs). MATERIALS AND METHODS: We evaluated the accuracy of 99mTc-sestamibi single-photon emission CT (SPECT/CT) imaging to characterize histologically diagnosed renal masses using 2 cohorts of patients; one from a prospective scan-and-resect clinical trial and a second from routine clinical care. The rate of renal mass positivity (ie, "hot tumors") on 99mTc-sestamibi SPECT/CT was stratified by histology. Diagnostic performance to identify histologic groupings of interest was measured by sensitivity and specificity. RESULTS: Three hundred forty-four patients with 361 tumors (124 trial, 237 clinical) were included. Most clear cell RCC (97%) and papillary or clear cell papillary RCC (80%-84%) were cold while chromophobe RCCs were equally likely to be hot or cold (52% vs 48%). Surgically resected oncocytomas tended to be hot (69%), with even higher positivity for biopsy with oncocytic neoplasms in the clinical cohort (87%). Limitations included the heterogeneous nature of the cohort and the use of biopsy for histologic diagnosis in the clinical cohort. CONCLUSIONS: 99mTc-sestamibi SPECT/CT is a novel method to effectively risk-stratify indeterminate renal masses. As with any nonsurgical method for renal mass characterization, there are potential false positives and false negatives, and those should be weighed carefully in shared decision-making with the patient to guide further evaluation and management.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Rowe SP, Murtazaliev S, Amindarolzarbi A, et al. Performance of 99mTc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience. J Urol. 2025. PMID: 41433425. doi:10.1097/JU.0000000000004911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。